That subjectivity is more than an academic inconvenience. Because skin thickening is one of the most measurable manifestations of systemic sclerosis, any imprecision in tracking it ripples through every aspect of care. A patient whose disease is genuinely improving may appear stable if the examiner’s touch differs from that of the previous visit. In clinical trials, where the skin score often serves as a key outcome measure, inter-observer variability can obscure whether an experimental therapy is actually working. Researchers have long argued that the absence of a precise, objective, and repeatable way to quantify skin fibrosis is one of the major barriers slowing the development of the first approved therapies specifically targeting skin fibrosis in this disease.

Now a team at Boston University Chobanian & Avedisian School of Medicine and the university’s Department of Biomedical Engineering reports a potential solution drawn from an unexpected corner of optics research. In a prospective cohort study published in The Lancet Rheumatology, the investigators describe the first application of a camera-based technique called spatial frequency domain imaging, or SFDI, to scleroderma. The method involves projecting patterns of harmless, non-contact light onto the skin and analyzing how those patterns are absorbed and scattered as they bounce back to a camera. Because collagen-rich, fibrotic tissue scatters and absorbs light differently from healthy skin, the returning signal carries quantitative information about what lies beneath the surface, all without ever touching the patient.

Darren Roblyer, professor of biomedical engineering and a co-author of the manuscript, noted that the technology has been a long time coming. His laboratory has spent nearly fifteen years developing SFDI for various biomedical applications, but this study marks the first time the technique has been directed at scleroderma. The adaptation matters because the optical properties that SFDI measures are sensitive to exactly the changes that define the disease: increased collagen deposition, altered tissue architecture, and the fibrotic remodeling that stiffens skin from within. In principle, a camera and a structured light source could do what a clinician’s fingers cannot—produce a number that means the same thing regardless of who takes the measurement.

To test that principle rigorously, the research team enrolled 49 people with scleroderma and 25 healthy volunteers at the Boston Medical Center Scleroderma Clinic. Each participant underwent SFDI imaging at six anatomical sites spanning the hands, forearms, and fingers, regions where skin thickening in systemic sclerosis typically appears early and progresses in characteristic patterns. The investigators then systematically compared the optical readings against the full battery of assessment tools already in clinical use. These included the physician’s touch-based skin score, ultrasound measurements of skin thickness, and a handheld device that quantifies skin hardness. Crucially, they also obtained forearm skin biopsies from 34 patients and 16 healthy volunteers, allowing the light-based measurements to be validated directly against the amount of collagen buildup visible in tissue under the microscope.

The results were strikingly consistent. Light readings were lower in people with scleroderma than in healthy individuals, and lower readings correlated with worse outcomes across every comparator: higher clinical skin scores, more scarring in the biopsy specimens, and thicker skin on ultrasound. Corresponding author Andreea Bujor, associate professor of medicine and a rheumatologist at Boston Medical Center, explained that the team compared the light readings directly with collagen accumulation in the biopsies, linking the imaging measurements to the scarring in the skin, and also tested repeatability and whether the readings changed as patients’ skin changed over time. In 11 patients, measurements were repeated longitudinally, and the optical signal tracked the direction of change in the clinical skin score, an early but important sign that the technique can follow disease evolution rather than merely snapshot it.

Perhaps the most intriguing finding was what SFDI detected in skin that doctors had scored as normal. Optical readings differed in those clinically unremarkable areas, suggesting the camera may perceive subtle collagen changes before they become palpable to even a trained hand. If confirmed in larger and longer studies, this sensitivity could shift the diagnostic timeline. Earlier detection of fibrotic change is a critical goal in systemic sclerosis because earlier diagnosis and treatment help improve prognosis and survival. A tool that flags subclinical skin involvement could allow physicians to intervene at a stage when antifibrotic strategies have a better chance of preserving tissue function, and could give trial designers a more sensitive endpoint for measuring whether new drugs slow or reverse the process.

The implications for drug development may be where the technology carries the greatest weight. With no approved therapies specifically for skin fibrosis in scleroderma, a fast, painless, non-contact measurement could help doctors track skin changes more objectively, help clinical trials detect treatment benefits more reliably, and identify subtle skin changes before they can be felt by hand, as Bujor emphasized. Clinical trials in fibrotic diseases are notoriously difficult because slow disease progression and noisy outcome measures can make even a genuinely beneficial therapy appear ineffective. An objective optical endpoint, standardized across sites and examiners, could reduce the sample sizes and trial durations needed to demonstrate efficacy, potentially lowering the cost and risk of bringing antifibrotic candidates to patients.

The study’s design also speaks to its credibility as an observational, prospective cohort effort. By anchoring the optical measurements to histological collagen content rather than relying solely on clinical scores, the researchers established a direct biological link between what the camera sees and what is actually happening in the tissue. The multi-modal comparison—touch, ultrasound, hardness, and biopsy—provides convergent validity from independent physical principles, while the repeatability testing addresses the practical question of whether the technique is stable enough for serial use in a clinic. The work received support from the National Scleroderma Foundation, the Scleroderma Clinical Trials Consortium, and the National Institutes of Health through the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Biomedical Imaging and Bioengineering.

As with any first-in-field study, caveats remain. The cohort was modest in size, the longitudinal follow-up included only 11 patients, and the measurements were performed at a single scleroderma center, so broader validation across diverse populations and clinical settings will be needed before SFDI can join routine practice. The authors’ declared relationships with industry, disclosed as unrelated to the submitted work, underscore how much commercial and therapeutic interest is converging on fibrosis measurement. Still, the trajectory is clear: a technology refined over fifteen years in an engineering laboratory has, in a single prospective study, demonstrated that patterns of light reflected from the skin can quantify the collagen that scleroderma deposits there—objectively, painlessly, and without a single pinch. For patients whose disease has long been assessed by touch alone, the prospect of a camera that sees fibrosis coming before fingers can feel it represents a meaningful step toward earlier treatment and, ultimately, better outcomes.

Subject of Research: Spatial frequency domain imaging for objective assessment of skin fibrosis and collagen accumulation in systemic sclerosis

Article Title: BU researchers develop simple, noninvasive way to assess collagen in the skin of scleroderma patients

Article References: BU researchers develop simple, noninvasive way to assess collagen in the skin of scleroderma patients. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: scleroderma, systemic sclerosis, skin fibrosis, collagen, spatial frequency domain imaging, SFDI, optical imaging, biomedical engineering, autoimmune disease, clinical trials, Boston University, The Lancet Rheumatology

The technology at the heart of this effort, chimeric antigen receptor T-cell therapy, involves extracting a patient’s own T lymphocytes and genetically engineering them to express an artificial receptor that recognises a specific molecular target. In oncology, the most common target is CD19, a protein displayed by many B-cell malignancies, but the same target has proved decisive in autoimmunity for a different reason: pathogenic B cells drive diseases such as systemic lupus erythematosus, myositis and systemic sclerosis. When engineered CAR T cells encounter CD19-expressing B cells, they eliminate them with a depth that conventional immunosuppressive drugs rarely achieve, and in doing so they can interrupt the autoimmune cascade at its source. Early clinical reports have described patients with severe, treatment-refractory disease entering drug-free remission after a single infusion, an outcome that would have seemed implausible only a few years ago.

Yet the expert panel is emphatic that enthusiasm must be tempered by caution. CAR T-cell therapy remains an evolving discipline in autoimmunity, with most evidence derived from small, single-arm studies rather than large randomised trials. Because high-level evidence is still emerging, the recommendations were constructed using the EBMT’s structured practice harmonisation methodology, a formal consensus process designed precisely for situations where clinical practice is racing ahead of definitive data. The result is not a rigid protocol but a shared framework: a set of expectations about who should be treated, where, by whom, and with what degree of monitoring before and after the cells are infused.

The cornerstone of the framework is patient selection. The consensus recommends considering CAR T-cell therapy only for patients with severe autoimmune disease that remains active or progressive despite appropriate standard treatment, meaning that conventional therapies must have been given a genuine opportunity to work before the cellular option is pursued. Whenever possible, the experts say, treatment should be delivered within the controlled environment of a clinical trial, where systematic data collection can accelerate the field’s understanding of efficacy and risk. When trial participation is not feasible, the decision to proceed should be documented through a multidisciplinary assessment involving both autoimmune disease specialists and haematology or cellular therapy experts, ensuring that perspectives from both sides of this unusual therapeutic border are represented before an irreversible step is taken.

Where the therapy is delivered matters as much as who receives it. The recommendations call for treatment in experienced centres, preferably those accredited by FACT or JACIE for immune effector cell therapies, because accreditation signals consistent quality and safety standards in cell processing, manufacturing oversight and toxicity management. The panel also stresses that autoimmune diseases differ enormously from one another in organ involvement, comorbidity burden and prior treatment exposure, so disease-specific assessment and monitoring remain essential even within a common framework. A patient with refractory lupus nephritis, a patient with severe multiple sclerosis and a child with juvenile dermatomyositis present distinct anatomical and immunological challenges, and the guidance explicitly resists the temptation to impose a one-size-fits-all pathway on this heterogeneity.

Raffaella Greco of San Raffaele Hospital in Milan and Dominique Farge of St-Louis Hospital in Paris, who coordinated the consensus process, framed the initiative as a balance between promise and prudence. CAR T-cell therapy, they noted, is emerging as an important new therapeutic approach for patients with severe and refractory autoimmune diseases, but the field is evolving rapidly, and careful patient selection, multidisciplinary management and long-term follow-up are essential. Their stated aim is a shared framework that supports patient safety and greater consistency in clinical practice while the evidence base continues to be built, a formulation that captures the panel’s central tension: how to standardise care without freezing a science that is still moving.

A substantial portion of the guidance concerns what happens around the infusion itself. The recommendations place strong emphasis on activities before and after CAR T-cell administration, including diagnostic assessment, treatment planning, immune monitoring and the management of treatment-related toxicities. One of the most clinically demanding challenges highlighted is the need to distinguish inflammatory complications caused by the therapy, such as cytokine release syndrome or immune effector cell-associated neurotoxicity, from a flare or progression of the underlying autoimmune disease. These entities can overlap in presentation, and misattributing one for the other can lead to harmful treatment decisions. The panel therefore calls for close collaboration between haematology, cellular therapy and autoimmune disease teams, so that the interpretation of fevers, neurological changes or serological shifts is informed by expertise on both sides.

Long-term follow-up and systematic data collection emerge as the panel’s most urgent priorities. The experts strongly recommend reporting every patient treated with CAR T-cell therapies to the EBMT Registry, a step intended to build understanding of long-term outcomes, durability of response and late toxicities. This emphasis echoes recent statements from both the United States Food and Drug Administration and the European Medicines Agency, which have underscored the need for extended surveillance of patients receiving these genetically modified cells. Because CAR T cells can persist in the body for years and deplete B-cell lineages for prolonged periods, questions about hypogammaglobulinaemia, infection risk, secondary malignancy and immune reconstitution cannot be answered without registry-scale data. The EBMT Registry has accordingly been expanded to support structured follow-up of patients with autoimmune diseases across participating centres, converting scattered clinical anecdotes into a coherent evidence base.

Children and adolescents receive dedicated attention in the update, reflecting both the particular vulnerability of younger patients and the relative scarcity of paediatric evidence. The recommendations call for multidisciplinary assessment that weighs disease severity and previous treatments against factors unique to growing patients: organ damage accumulated during development, fertility preservation, quality of life and the long-term consequences of chronic immunosuppression, which in young patients can span decades. The calculus of offering a single potentially curative infusion to a teenager instead of a lifetime of steroid and immunosuppressant exposure is compelling, but the panel insists that the limited paediatric data demand heightened deliberation rather than reduced scrutiny.

Looking forward, the authors identify priorities that will shape the next phase of research: larger controlled clinical trials to establish efficacy beyond single-arm cohorts, biomarkers capable of predicting which patients will respond and which will suffer toxicity, novel CAR targets that might extend the approach beyond B-cell-driven disease, and strategies to improve treatment access so that the therapy does not remain confined to a handful of specialised centres. The 2026 recommendations are explicitly conceived as living guidance under the auspices of EBMT, ISCT and JACIE, and they will continue to evolve as new evidence and clinical experience emerge. For now, they represent the most comprehensive attempt yet to impose scientific discipline on one of the most exciting developments in modern immunology, ensuring that as CAR T cells march from the oncology ward into the rheumatology clinic, they do so under conditions designed to protect the very patients they are meant to help.

Subject of Research: Consensus recommendations for CAR T-cell therapy in severe autoimmune diseases

Article Title: International consensus sets updated framework for CAR T-cell therapy in severe autoimmune diseases

Article References: International consensus sets updated framework for CAR T-cell therapy in severe autoimmune diseases. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: CAR T-cell therapy, autoimmune diseases, EBMT, ISCT, JACIE, The Lancet Rheumatology, patient selection, immune monitoring, long-term follow-up, clinical trials, paediatric care, registry data